Abstract
One approach to identify new drugs with antimicrobial activities is to screen large libraries of molecules directly for their capacity to block the growth of bacterial or fungal monocultures. A more relevant way to assess both a products efficacy and its potential cytotoxicity is undoubtedly to use an in vivo infection system. Testing banks containing thousands of natural or chemically synthesized molecules with rodents is generally neither desirable nor feasible. Therefore, invertebrate model organisms could represent a valuable alternative. In this review, we present the worm C. elegans as a suitable host model for the evaluation and characterization of drug effects in a pathogenesis context. This simple organism has been of great value in many fields of biology and is currently intensely used in studies of hostpathogen interactions. Infection of C. elegans induces a number of defense mechanisms, some of which are similar to those seen in mammalian innate immunity. Further, it has been demonstrated that several microbial virulence mechanisms required for full pathogenicity in mammals are also necessary for infection in nematodes. Based on these facts, a number of innovative antimicrobial drug screens have been carried out successfully and the development of new tools to monitor the interaction between worm and microbes in vivo opens promising perspectives.
Keywords: Antimicrobial, C. elegans, high-throughput, infection, pathogen, screen, drug discovery, microbes, host sress response, virulence
Current Drug Targets
Title: C. elegans: An All in One Model for Antimicrobial Drug Discovery
Volume: 12 Issue: 7
Author(s): B. Squiban and C. Leopold Kurz
Affiliation:
Keywords: Antimicrobial, C. elegans, high-throughput, infection, pathogen, screen, drug discovery, microbes, host sress response, virulence
Abstract: One approach to identify new drugs with antimicrobial activities is to screen large libraries of molecules directly for their capacity to block the growth of bacterial or fungal monocultures. A more relevant way to assess both a products efficacy and its potential cytotoxicity is undoubtedly to use an in vivo infection system. Testing banks containing thousands of natural or chemically synthesized molecules with rodents is generally neither desirable nor feasible. Therefore, invertebrate model organisms could represent a valuable alternative. In this review, we present the worm C. elegans as a suitable host model for the evaluation and characterization of drug effects in a pathogenesis context. This simple organism has been of great value in many fields of biology and is currently intensely used in studies of hostpathogen interactions. Infection of C. elegans induces a number of defense mechanisms, some of which are similar to those seen in mammalian innate immunity. Further, it has been demonstrated that several microbial virulence mechanisms required for full pathogenicity in mammals are also necessary for infection in nematodes. Based on these facts, a number of innovative antimicrobial drug screens have been carried out successfully and the development of new tools to monitor the interaction between worm and microbes in vivo opens promising perspectives.
Export Options
About this article
Cite this article as:
Squiban B. and Leopold Kurz C., C. elegans: An All in One Model for Antimicrobial Drug Discovery, Current Drug Targets 2011; 12 (7) . https://dx.doi.org/10.2174/138945011795677854
DOI https://dx.doi.org/10.2174/138945011795677854 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs
Current Medicinal Chemistry The Interrelationship Between Disease and Ageing and the Implications for Longevity
Current Aging Science Comparative Approach of the de novo Fatty Acid Synthesis (Lipogenesis) between Ruminant and Non Ruminant Mammalian Species: From Biochemical Level to the Main Regulatory Lipogenic Genes
Current Genomics Potential Interactions of Carotenoids with Other Bioactive Food Components in the Prevention of Chronic Diseases
Current Bioactive Compounds Protein/ Hormone Based Nanoparticles as Carriers for Drugs Targeting Protein-Protein Interactions
Current Topics in Medicinal Chemistry Prostacyclin, Atherothrombosis and Diabetes Mellitus: Physiologic and Clinical Considerations
Current Molecular Medicine Medicinal Treatments of Cholesterol Gallstones: Old, Current and New Perspectives
Current Medicinal Chemistry The Melatonin and Enriched Environment Ameliorated Low Protein-Induced Intrauterine Growth Retardation by IGF-1 And mtor Signaling Pathway and Autophagy Inhibition in Rats
Current Molecular Medicine Diabetic Cardiovascular Disease – AMP-Activated Protein Kinase (AMPK) as a Therapeutic Target
Cardiovascular & Hematological Agents in Medicinal Chemistry A Review on Pharmacological and Clinical Aspects of Linum usitatissimum L.
Current Drug Discovery Technologies Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Recent Patents in Pulmonary Delivery of Macromolecules
Recent Patents on Drug Delivery & Formulation Factors Modulating Fibrates Response: Therapeutic Implications and Alternative Strategies
Endocrine, Metabolic & Immune Disorders - Drug Targets Benefits of Exercise Training in Secondary Prevention of Coronary and Peripheral Arterial Disease
Vascular Disease Prevention (Discontinued) The Dual Role of Free Fatty Acid Signaling in Inflammation and Therapeutics
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Disrupting the mTOR Signaling Network as a Potential Strategy for the Enhancement of Cancer Radiotherapy
Current Cancer Drug Targets An Overview on Natural Polysaccharides with Antioxidant Properties
Current Medicinal Chemistry Quetiapine to Treat Agitation in Dementia: A Randomized, Double-Blind,Placebo-Controlled Study
Current Alzheimer Research Road to Future: iPSC Clinical Application in Parkinson’s Disease Treatment
Current Molecular Medicine “Self-Antigenic Universe” and Tuberculosis Vaccine Development
Current Pharmacogenomics and Personalized Medicine